A European Perspective On Testicular Tissue Cryopreservation For Fertility Preservation In Prepubertal And Adolescent Boys by ,
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A European Perspective On Testicular Tissue Cryopreservation
For Fertility Preservation In Prepubertal And Adolescent Boys
Citation for published version:
on behalf of the ESHRE Task Force On Fertility Preservation In Severe Diseases 2015, 'A European
Perspective On Testicular Tissue Cryopreservation For Fertility Preservation In Prepubertal And Adolescent
Boys' Human Reproduction, vol. 30, no. 11, pp. 2463-75. DOI: 10.1093/humrep/dev190
Digital Object Identifier (DOI):
10.1093/humrep/dev190
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Human Reproduction
Publisher Rights Statement:
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Human Reproduction
following peer review. The definitive publisher-authenticated version is available online at:
http://humrep.oxfordjournals.org/content/early/2015/09/10/humrep.dev190.long
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
  
1 
Title  1 
A European Perspective On Testicular Tissue Cryopreservation For Fertility Preservation In 2 
Prepubertal And Adolescent Boys  3 
 4 
Running Title  5 
Testicular Tissue Cryobanking In Boys And Adolescents 6 
 7 
Authors 8 
Helen M Picton1, Christine Wyns2 , Richard A Anderson3, Ellen Goossens4, Krisi Jahnukainen5, 9 
Sabine Kliesch6,  Rod T Mitchell3, G Pennings7 , Natalie Rives8,  Herman Tournaye9, Ans MM Van 10 
Pelt10 , Ursula Eichenlaub-Ritter11, Etienne Van den Abbeel12, Stefan Schlatt6 11 
On behalf of the ESHRE Task Force On Fertility Preservation In Severe Diseases  12 
 13 
Addresses 14 
1 Division of Reproduction and Early Development, Leeds Institute of Cardiovascular and 15 
Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Clarendon Way, Leeds, 16 
UK. 17 
 18 
2Université Catholique de Louvain (UCL), Pôle de Recherche en Gynécologie, Institut de 19 
Recherche Expérimentale et Clinique (IREC), 1200 Brussels, Belgium and 20 
Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 21 
1200 Brussels, Belgium 22 
 23 
3MRC Centre for Reproductive Health, Queens Medical Research Institute, University of 24 
Edinburgh, Edinburgh UK. 25 
 26 
  
2 
4Research Group Biology of the Testis (BITE), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 27 
Brussels 28 
 29 
5Children´s Hospital, Helsinki University Central Hospital, Helsinki, Finland and Department of 30 
Women’s and Children´s Health, Karolinska Institute and University Hospital, Stockholm                          31 
 32 
6Centre of Reproductive Medicine and Andrology, University Münster, Domagkstraße 11, 48149 33 
Münster, Germany 34 
 35 
7Bioethics Institute Ghent (BIG), Faculty of Philosophy and Moral Science, Ghent University, 36 
Belgium 37 
 38 
8Laboratoire de Biologie de la Reproduction – CECOS, Research team EA 4308 "Gametogenesis 39 
and gamete quality", IRIB, Rouen University Hospital, University of Rouen, 76031 Rouen cedex, 40 
France 41 
 42 
9Centre for Reproductive Medicine, University Hospital of the Brussels Free University, 43 
Laarbeeklaan 101, 1090 Brussels , Belgium  44 
 45 
10Center for Reproductive Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ 46 
Amsterdam, The Netherlands  47 
 48 
11Faculty of Biology, Gene Technology/Microbiology, University of Bielefeld, Bielefeld 33501, 49 
Germany. 50 
12IVF lab- Center for Reproductive Medicine, University Hospital Gent, De Pintelaan 185, 9000 51 
Gent, Belgium. 52 
  
3 
 53 
  54 
  
4 
ESHRE Task Force On Fertility Preservation In Severe Disease 55 
 56 
Corresponding Author 57 
HM Picton, Division of Reproduction and Early Development, Leeds Institute Cardiovascular and 58 
Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Clarendon Way, Leeds, 59 
UK. LS2 9JT 60 
Email: H.M.Picton@leeds.ac.uk,  Fax +44 (0)113 343 6603 61 
 62 
  63 
  
5 
Abstract 64 
This Task Force paper explores the evidence base for fertility preservation in prepubertal boys and 65 
adolescents. It provides an overview of the current best clinical practices, patient management 66 
strategies and experimental methods used to preserve and restore the fertility for young male 67 
patients. Collection and cryopreservation of semen is acknowledged as the proven first line 68 
treatment for fertility preservation in adolescent males. However, semen retrieval is not possible in 69 
prepubertal boys and may not always be feasible in adolescents. For these young patients 70 
practitioners are already looking towards the experimental treatments of testicular tissue 71 
cryopreservation and the harvesting and banking of isolated spermatogonial stem cells as viable 72 
means of preserving fertility. Results of a recent survey of testis freezing practices in young patients 73 
from 24 European and Israeli university hospitals prior to December 2012 indicate that more than 74 
260 young patients (age range less than 1 year old to 16 years of age), had already undergone 75 
testicular tissue retrieval and storage for fertility preservation. In the greater majority of these cases 76 
tissue was cryobanked for boys prior to onset of oncological treatments.  In light of this evidence, 77 
the ethical and legal challenges and outstanding clinical and research questions are discussed and an 78 
algorithm for the cryopreservation of sperm and testicular tissue in pre-pubertal and adolescent 79 
patients at high risk of infertility is proposed. 80 
 81 
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1. Introduction 84 
Cancer is a major cause of non-accidental mortality in children and adolescents. However, as a 85 
result of the remarkable improvements in treatments, childhood and adolescent cancer mortality 86 
rates are now declining with significant declines being recorded for multiple cancer types (Smith et 87 
al., 2014).  Results from European and American data suggest that long-term survival can be 88 
expected in approximately 80% of the children and adolescent diagnosed with cancer (Desandes, 89 
2007; Hudson 2010). Indeed, recent estimates suggest that approximately 1 in 530 young adults 90 
between the ages of 20 and 39 is a childhood cancer survivor (Ward et al., 2014). Unfortunately, 91 
just like the rapidly dividing malignant cells that are their primary targets, proliferating 92 
spermatogonial stem cells (SSCs) in the testis are damaged by exposure to chemotherapy agents 93 
and radiation treatments. Thus the treatments used to cure the cancer may render the patients 94 
temporarily or permanently infertile. Furthermore, gonadotoxic treatments are increasingly used to 95 
cure a range of non-malignant conditions in children. Finally, underlying genetic causes such as 96 
Klinefelter’s syndrome may lead to premature germ line stem cell loss in boys (Gies et al., 2012; 97 
Van Saen et al., 2012; Rives et al., 2013).   98 
 99 
As the loss of fertility in adult life following childhood illness is becoming increasingly 100 
unacceptable different Different strategies are beinghave been developed to safeguard the fertility of 101 
these young patients. Cryopreservation of spermatozoa is routinely used to preserve fertility in men 102 
(for example, Sharma 2011), and there is an increasing evidence base documenting the efficacy of 103 
sperm cryopreservation as the first line fertility preservation treatment in adolescents (Daudin et al., 104 
2015). However, for some adolescents it may not be possible to recover sperm prior to the onset of 105 
ablative therapies and semen production is clearly not an option for prepubertal boys. Testicular 106 
tissue and SSC cryopreservation are therefore now being considered as experimental strategies for 107 
fertility preservation in those young individuals who are facing the prospects of loss of their SSCs 108 
as a result of exposure to gonadotoxic therapies or for genetic conditions. This summary paper will 109 
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7 
provide a comprehensive review of the best clinical practices andthe evidence base forcurrent 110 
practices used for fertility preservation in prepubertal boys and adolescents. It will provide insights 111 
into the state of the art of SSC and testicular tissue cryopreservation as means to preserve the future 112 
fertility in young patients. . The reader is referred to accompanying long version of this paper for 113 
detailed overview of the cytotoxic impact of chemotherapy and radiations treatments on the testis 114 
and subsequent disruption of future fertility in boys and adolescents that underpins the need for 115 
fertility preservation in these young patients.  116 
 117 
2. The Gonadotoxicity Of Chemotherapy And Radiation Treatments  118 
Chemotherapy agents and radiation treatments have been shown to adversely affect the male 119 
germinal epithelium. The amount of damage depends on the regimen and the cumulative dosage of 120 
treatments used (Van der Meer et al., 1993; Wyns et al., 2010). Testicular cells and especially 121 
dividing germ cells (spermatogonia) are highly sensitive to cytotoxic treatments. Low doses of 122 
these treatments deplete the pool of differentiating spermatogonia, while proliferating SSCs may 123 
initially survive and spermatocytes and spermatids continue their maturation into sperm (van 124 
Alphen et al., 1988). Testicular involution after such gonadotoxic damage is a slow process that 125 
takes several weeks in sexually mature men until temporary or permanent azoospermia ensues.  126 
 127 
The recovery of sperm production after a cytotoxic insult in adulthood or at puberty depends on the 128 
ability of quiescent SSCs to survive and resume mitotic activity to produce differentiating 129 
spermatogonia (van Alphen et al., 1988). If the damage is severe all SSCs may commit to apoptosis 130 
and the patient will become permanently sterile. Spermatogonia have been shown to be susceptible 131 
to such depletion at all stages of life (Whitehead et al., 1982; Relander et al.; 2000; Jahnukainen et 132 
al., 2011b). Indeed, the presence of a steady turnover of spermatogonia that undergo spontaneous 133 
degeneration before the haploid stage is reached (Muller and Skakkebaeck, 1983; Kelnar et al., 134 
2002; van Alphen et al., 1988) may explain why the prepubertal state does not offer any protection 135 
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against the deleterious effect of chemotherapy and irradiation. Furthermore, patient age, previous 136 
testicular disorders and the individual susceptibility to cancer treatment toxicity may also influence 137 
the potential of the seminiferous epithelium to support spermatogenesis after treatment (Rives et al., 138 
2012). In addition, the different cellular compartments in the testis respond to toxic insults in 139 
different ways.  140 
 141 
Chemotherapy-induced damage to the testis 142 
The impact of chemotherapy agents on the spermatogenic epithelium is dependent on the type, 143 
dosage of and combination of drugs used (Wallace et al., 2005; Aubier et al., 1989; Siimes and 144 
Rautonen, 1990; Wyns et al., 2010, Figure 1); in some circumstances even one course of cytotoxic 145 
chemotherapy can lead to azoospermia. Acute leukaemia, the most common cancer type in children, 146 
involves treatment with antimetabolites and vinca-alkaloids that inhibit DNA and RNA synthesis 147 
and mitosis. Long-term follow-up of childhood leukaemia survivors indicates that treatment with 148 
these cell cycle specific cytotoxic drugs, without a high dose of alkylating agents such as 149 
cyclophosphamide, does not totally deplete SSCs and that spermatogenesis may be reinitiated from 150 
the surviving SSCs (Jahnukainen et al., 2011c; Nurmio et al., 2009). The threshold dose of 151 
cyclophosphamide, in relation to infertility, has been shown to be between 7.5 and 10 g/m2 (Aubier 152 
et al., 1989; Meistrich et al., 1992; Rivkees and Crawford 1988). Slow recovery of spermatogenesis 153 
may occur even after such high doses whereas permanent sterility may appear after 19-20 g/m2 dose 154 
of cyclophosphamide (Gurgan et al., 2008; Jahnukainen et al., 2011c). Other alkylating agents and 155 
platinum containing compounds such as carboplatin and cisplatin have also been reported to have a 156 
threshold dose above which there is an increased incidence of testicular failure (Figure 1, Meistrich 157 
et al., 1992; Gurgan et al., 2008; Bokemeyer et al., 1994; Wyns et al., 2010; Lampe et al., 1997; 158 
Meistrich et al., 1989). Both alkylating- and platinum containing- agents cause direct DNA and 159 
RNA damage and so can affect even non-dividing, reserve stem cells. Germ cell toxicity is 160 
therefore a significant late effect of conditioning for hematopoietic stem cell transplantation such 161 
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that germ cell depletion with raised serum FSH and decreased testicular growth in puberty is 162 
observed among most male patients (van Casteren et al., 2009; Anserini et al., 2002). Long term 163 
spermatogenetic recovery is more likely after chemotherapy than after total body irradiation based 164 
conditioning regimens (Anserini et al., 2002). Evidence for impairment of Sertoli cell function 165 
following chemotherapy has also been reported (Bar-Shira Maymon et al., 2004).  166 
 167 
Chemotherapy-induced Leydig cell failure resulting in androgen insufficiency and requiring 168 
testosterone replacement therapy is rare (Sklar 1999). The majority of males undergo a normal 169 
puberty and most produce normal adult levels of testosterone. Compensated Leydig cell failure has 170 
been reported in patients treated with a combination of mustine and procarbazine for Hodgkin 171 
disease and also after treatment with high doses of cyclophosphamide (Meistrich et al., 1992; 172 
Heikens et al., 1996; Bramswig et al., 1990). In contrast, young boys and adolescent males who 173 
receive 200 mg/kg (6.7 g/m2) cyclophosphamide or a combination of busulphan and 174 
cyclophosphamide as conditioning therapy for bone marrow transplantation appear to retain normal 175 
Leydig cell function (Sarafoglou et al., 1997). 176 
 177 
Irradiation-induced damage to the testis 178 
The germinal epithelium is very susceptible to radiation-induced damage. The extent of these 179 
effects depends on the field of treatment, total dose and fractionation (Brauner et al., 1983; Sklar et 180 
al., 1990; Van der Meer et al., 1993). Differentiating spermatogonia are radiosensitive to scattered 181 
doses as low as 0.1 Gy leading to short term cessation of spermatogenesis (Rowley et al., 1974). 182 
Doses of 2–3 Gy also affect SSCs and cause long-term azoospermia (van Alphen et al., 1989), 183 
whereas doses in excess of 6 Gy deplete the SSC pool and can lead to permanent infertility (Rowley 184 
et al., 1974; Centola et al., 1994). Fractionation of radiotherapy increases the germ cell toxicity 185 
because repeated hits to activated reserve stem cells (Centola et al., 1994; Ash 1980)  and total body 186 
irradiation (TBI), used as conditioning for haematological stem cell transplantation, is associated 187 
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with significant germ cell failure (Sarafoglou et al., 1997). Indeed, following TBI (10 or 13 Gy), 188 
azoospermia has been reported in 85% of men with oligozoospermia (Anserini et al., 2002) and  189 
spermatogenesis did not recover until the 4th year after transplantation. Furthermore, azoospermia 190 
after hematopoietic stem cell transplantation may be overestimated if sperm samples are evaluated 191 
too early after transplantation (Anserini et al., 2002).  192 
 193 
Leydig cells are susceptible to damage from external irradiation although the dose required is much 194 
higher than that needed to cause germ cell failure. Leydig cell damage is dose-dependent and is 195 
inversely related to patient age at treatment, such that pubertal or younger males receiving 24Gy for 196 
testicular leukaemia are at a high risk of delayed sexual maturation associated with decreased 197 
testosterone levels and they require androgen replacement therapy (Brauner et al., 1983; Sklar et al. 198 
1990). In contrast, the majority of males receiving 20Gy of fractionated testicular irradiation appear 199 
to retain their ability to produce normal amounts of testosterone (Sklar 1999; Sarafoglou 1997); 200 
elevated LH in these patients may indicate compensated Leydig cell failure as with some 201 
chemotherapy regimens. 202 
 203 
Sperm damage following chemotherapy or radiation treatment  204 
Apart from the cytotoxic effects detailed above, anti-neoplastic treatments have also been shown to 205 
have genotoxic effects (i.e. aneugenic, clastogenic and mutagenic) on male germ cells at different 206 
stages of maturation (Russo et al., 2000; Adler et al., 2012). Cancer treatments may induce a range 207 
of chromosome abnormalities in mature spermatozoa including: aneuploidy; structural 208 
rearrangements and alterations of chromosomes including sister chromatid exchanges; simple or 209 
double strand breaks; mutations; and micronucleus formation (Russo et al., 2000; Arnon et al., 210 
2001; Adler et al., 2012). Sperm DNA damage may have a negative impact on male fertility and 211 
although in many cases these spermatozoa will not be able to fertilize oocytes when fertilization 212 
does occur, genetic damage may be transmitted to the next generation (Arnon et al., 2001) as 213 
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manifest by: (i) abnormal embryo development; (ii) undetected and detected spontaneous abortion; 214 
(iii) malformations in offspring; or (iv) diseases later in life of the progeny.  215 
 216 
While much of the evidence demonstrating the genotoxic effects of cancer treatments on 217 
spermatozoa have been derived from animal studies (Adler et al., 2012), reports on sperm DNA 218 
damage in humans have also been obtained following exposure to multiple drugs or treatment 219 
regimens used for common malignancies. For example, data have been derived both from young 220 
adult males with testicular cancer, Hodgkin’s lymphoma or non Hodgkin’s lymphoma (Tempest et 221 
al., 2008; Burello et al., 2011; Smit et al., 2010) and from survivors of childhood cancer (Thomson 222 
et al., 2002; Romerius et al., 2010). These studies are frequently retrospective with different time 223 
frames of follow-up and the number of patients involved is often low. Furthermore, treatment 224 
regimens are variable and depend on the type of malignancy and sperm DNA damage is often 225 
evaluated using only one parameter of DNA alteration such as aneuploidy, defective chromatin 226 
compaction, or sperm DNA fragmentation. Very few prospective studies have directly investigated 227 
sperm DNA damage prior to, during and/or after treatment (Tempest et al., 2008; Burello et al., 228 
2011; Smit et al., 2010) and in general the data lack consistency. For example, sperm DNA breaks 229 
and low chromatin compaction were detected for up to 24 months post chemotherapy in survivors 230 
of testicular cancer and Hodgkin’s lymphoma (O’Flaherty et al., 2012). In contrast, DNA damage 231 
was significantly reduced in post-treatment semen samples after 1.1 years in another study (Smit et 232 
al., 2010) whereas sperm DNA breaks were not increased in 23 childhood cancer survivors when 233 
compared to the healthy population (Thomson et al., 2002) but were impaired in young survivors 234 
treated with radiotherapy or surgery only (Romerius et al., 2010). In the case of testicular cancer 235 
and Hodgkin’s lymphoma in young adults, chemotherapy has been shown to significantly increase 236 
aneuploidy rates in sperm 6 months after the initiation of treatment. Thereafter, chromosomal errors 237 
generally declined to pre-treatment levels around 12 (Burrello et al., 2011) to 18 months after 238 
treatment onset (Tempest et al., 2008). Increased aneuploidy rates have been shown to persist in 239 
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some chromosomes for up to 24 months after drug exposure but other studies have reported no 240 
increased aneuploidy frequency after 24 months  but these data are based on small patient numbers 241 
(reviewed by Tempest et al., 2008). Another confounding factor is the influence of the cancer itself 242 
since it has been shown that both testicular cancer and Hodgkin’s lymphoma can exert a detrimental 243 
effect on chromosome segregation during the meiotic process prior to treatment and so can also lead 244 
to an increased rate of sperm aneuploidy prior to treatment (Tempest et al., 2008).  245 
 246 
One explanation for the discrepancies between studies is the observation that differentiating 247 
premeiotic and meiotic germ cells are more sensitive to the induction of mutations than SSCs. Thus 248 
the risk of transmission of genetic errors to the next generation is temporary and lasts for only a few 249 
months after treatment. In contrast, surviving SSCs containing mutations will continue to produce 250 
sperm with these mutations and if not repaired these may be transmitted to the next generation for 251 
the life time of the individual (reviewed in Meistrich 2009). Finally, epigenetic changes such as 252 
abnormal sperm methylation patterns are known to be associated with infertility and trans- 253 
generational effects (Kobayashi et al., 2009). Examination of rodent sperm after exposure to a 254 
combination chemotherapy regimen normally used for testicular cancer treatment, demonstrated 255 
that the anti-neoplastic treatment altered spermatozoa DNA methylation (Chan, 2011). Largely due 256 
to the lack of large prospective studies that simultaneously evaluate the impact of chemotherapy 257 
and radiation treatment on the risk of genetic and epigenetic alterations of spermatozoa, the 258 
consensus regarding fertility preservation is therefore that gamete storage should take place before 259 
the beginning of medical anti-neoplastic treatment (Menon et al., 2009; Rives et al., 2012; Nahata 260 
et al., 2013).  261 
 262 
 263 
3. Risks To The Offspring Of Male Survivors Of Childhood Cancer  264 
While the potential for reproductive loss or congenital abnormalities in the children born of cancer 265 
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survivors remains a concern, there are now sufficient populations of childhood cancer survivors who 266 
have reached their reproductive years to address this issue directly. Beyond the impact of sperm DNA 267 
damage on early embryo development, there are two main areas to address: risks associated with 268 
pregnancy i.e. stillbirth, and the possibility of increased risk of congenital abnormalities, genetic 269 
disease or neonatal death in the offspring of male childhood cancer survivors. The risk of stillbirth 270 
(defined in the US as occurring after 20 weeks of pregnancy) or neonatal death among the offspring 271 
of men who had survived childhood cancer have been reported in a retrospective cohort analysis 272 
within the Childhood Cancer Survivor Study (CCSS) (Signorello et al., 2010). Among 1148 men 273 
who had survived childhood cancer, there were 2031 pregnancies. Irradiation of the testes (16 [1%] of 274 
1270 men; adjusted relative risk 0·8 [95% CI 0.4–1.6] and chemotherapy with alkylating drugs (10 275 
[1%] of 732 men, adjusted relative risk 1.2 [0.5–2.5]) were not found to be associated with an 276 
increased risk of stillbirth or neonatal death. The risks of stillbirth (from 28 weeks of gestation), 277 
neonatal disease and genetic disease have been reported in a population-based cohort of 472 male and 278 
female Danish survivors of cancer in childhood and adolescence, that included 1,037 pregnancies 279 
(Winther et al., 2012). This study revealed that the risk of genetic disease was similar among the 280 
children of irradiated survivors compared with children born of non-irradiated survivors (RR 1.02, 281 
95% CI 0.59 to 1.44) and was unchanged amongst those who received alkylating agents both when 282 
compared with those who did not receive chemotherapy (RR 0.9, 95% CI 0.5 to 1.3) and those 283 
without any potential mutagenic treatment (RR 0.8, 95% CI 0.3 to 2.1).  284 
 285 
The risk of congenital abnormality or genetic disease in the children of male childhood cancer 286 
survivors is low. A Danish population-based cohort study of 1715 children born of 3,963 cancer 287 
survivor parents examined the association between gonadal radiation and risk of malformation in 288 
the offspring, including malformations diagnosed later in life (median follow-up time 8.2 years; 289 
Winther et al., 2009). The prevalence of congenital malformations in the offspring of cancer 290 
survivors was not increased when compared to either sibling controls or the general population, 291 
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either overall or when male and female cancer survivors were separated. The prevalence proportion 292 
ratio was 1.1 (95% CI 0.8 to 1.5) compared with sibling controls, and the observed to expected ratio 293 
was 1.2 (95% CI 0.9 to 1.6) when compared with the general population (Winther et al., 2009). 294 
There was also no detectable relationship with dose of gonadal radiotherapy. These reassuring 295 
findings support  the recent data from the CCSS on 4,699 children of 1128 male and 1627 female 296 
childhood cancer survivors, which again provides strong evidence that neither chemotherapy nor 297 
gonadal radiotherapy increase the risk of congenital abnormality in offspring (Signorello et al., 298 
2012). The prevalence of abnormality after testicular radiotherapy was 1.9%, vs. 1.7% following 299 
treatment with alkylating agents, and 2.1% in the offspring of men who did not receive 300 
radiotherapy. There was no relationship between testicular radiation dose and risk of congenital 301 
abnormality (OR 1.01; 95% CI, 0.36 to 2.83 for >5cGy). These data support previous analyses from 302 
the CCSS (Green et al., 2009). In contrast, a recent Swedish/Danish birth register study of 8670 303 
children whose fathers had cancer, compared with over 1.7 million children who did not, suggests a 304 
small increased risk of birth abnormalities, from 3.2% to 3.7% (RR 1.17, 95% CI 1.05 to 1.31) 305 
(Stahl et al., 2011). The increased risk applied to both natural and assisted conceptions and was 306 
higher if the child was born within 2 years of the father’s cancer diagnosis. The use of birth 307 
registers does not permit the analysis of the effects of specific cancer treatments. While these data 308 
demonstrate that the direct risks to the offspring of male childhood cancer survivors, both in terms 309 
of congenital abnormality and genetic disease, do not seem to be increased by either chemotherapy 310 
or radiotherapy, these studies only evaluated the risks to the offspring of long-term cancer 311 
survivors, they do not contradict the evidence presented for an increased risk in the short-term i.e. 312 
during and for the first 2 years after therapy. This important issue requires further investigation.  313 
 314 
 315 
4. Current Practices Of Fertility Preservation In Prepubertal Boys And Adolescents 316 
  
15 
The current interventions used to preserve fertility in males range from the use of validated clinical 317 
procedures such as semen collection and sperm cryopreservation to the adoption of experimental 318 
methodologies such as slow freezing or vitrification of immature testicular tissue or the use of 319 
research-based drug therapies that reduce or shield the testis from the gonadotoxic impact of 320 
chemotherapy or radiation treatments (Wyns et al., 2010). Hormonal approaches to conserve 321 
fertility have not proven to be useful in males (for review see Shetty and Meistrich, 2005) and anti-322 
apoptotic agents such as spingosine-1-phosphate have been shown to be of limited value 323 
(Suomalainen et al., 2003). Co-administration of the immunomodulating compound AS101 during 324 
cyclophosphamide treatment appears to provide protection against cytotoxic damage without 325 
attenuating the anticancer effect in animal studies. AS101 may act via Akt/GSK-3beta 326 
phosphorylation (Carmely et al., 2009). Whether AS101 has a similar protective effect in primate 327 
testes has yet to be evaluated.  328 
 329 
Sperm cryopreservation and storage for adolescent patients 330 
The fertility preservation strategy that has been used for many decades to safeguard the future 331 
fertility of adults (Crabbé et al., 1999; for review see Sharma 2011) and adolescents (Daudin et al., 332 
2015) is the cryopreservation and long-term storage of ejaculated or testicular spermatozoa. With 333 
regard to adolescent patients recommendations advocate that patients are informed of their need for 334 
fertility preservation and the options available to them as early as possible during the planning of 335 
their treatment (Lee et al., 2006). Indeed the presence of a cryostorage depot facility for 336 
spermatozoa has been shown to contribute positively to the patient’s psychological health and 337 
confidence in post-survival fatherhood in both adults and adolescents (Saito et al., 2005; Edge et 338 
al., 2006). Despite the fact that cryopreservation of spermatozoa is recognized as the only effective 339 
fertility preservation technique for males facing gonadotoxic treatments, a study performed in the 340 
US revealed that only about 50% of physicians offered cryopreservation to a quarter of their 341 
patients prior to the start of potentially gonadotoxic therapies (Schover et al., 2002).   A recent 342 
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study of 23 French regional sperm banks recorded considerable inter-centre variation in practices 343 
involving young patients seeking to preserve their fertility before cancer therapy (Daudin et al., 344 
2015). Indeed, it is mostly young adults who undertake sperm storage and the mean age varies 345 
depending on the underlying disease. Stable partnerships are rare in the younger males (up to 24%) 346 
(Kliesch et al., 2010, Behringer et al., 2012) and are not relevant when considering fertility 347 
preservation in prepubertal boys and adolescents. The most common malignant diseases for semen 348 
storage are testicular tumours, Hodgkin or Non-Hodgkin lymphoma, leukaemia or bone tumours 349 
with some additional non-malignant conditions with indications for gonadotoxic treatments 350 
(Kliesch et al., 2010; Daudin et al., 2015). Semen characteristics vary with both patient age and 351 
type of cancer (Daudin et al., 2015). However in testicular cancer patients, semen parameters may 352 
be significantly reduced at time of diagnosis compared to other malignancies with oligozoospermia 353 
occurring in up to 60% of cases. Approximately 60% of males with lymphoma or leukaemia are 354 
normozoospermic, but 14% of testis cancer patients are azoospermic (with an additional 5% with 355 
anejaculation) compared to only 3% azoospermia in lymphoma (Kliesch et al., 2010; van der Kaaij 356 
et al., 2009).  357 
  358 
Semen can be cryopreserved for adolescent boys in more than 80% of cases (Bahadur et al., 1999; 359 
Kliesch et al., 1996; van Casteren et al., 2008a; Menon et al., 2009; Daudin et al., 2015). The rate 360 
of azoospermia varies between 2.6 to 18% of patients (Menon et al., 2009; van Casteren et al., 361 
2008a). However, up to 15% of adolescent or adult patients may either fail to produce a semen 362 
sample or have insufficient spermatozoa present in the collected semen (see Table 1). In 363 
adolescents, measurements of testicular volume have been shown to be helpful in predicting the 364 
chance for successful retrieval of spermatozoa and semen production (Kliesch et al., 1996; 365 
Kamischke et al., 2004). As soon as spermatogenesis has been induced, semen parameters can be 366 
comparable to those of adult patients irrespective of the underlying disease (Kliesch et al., 1996; 367 
Kamischke et al., 2004) (Table 1).  368 
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 369 
The rules and recommendations for fertility preservation in males differ between countries. There 370 
are no strict limitations concerning semen quality or sperm numbers for fertility preservation 371 
strategies and there are no international guidelines for the duration of storage of spermatozoa, 372 
whether ejaculated or testicular. While standard semen evaluation and documentation according to 373 
World Health Organisation (WHO, 2010) criteria prior to sperm cryopreservation is valuable for 374 
fertility preservation patients, if vital sperm can be recovered even in small numbers then sperm 375 
storage is possible, as ARTs post-thaw will facilitate the selection and use of viable sperm for 376 
insemination (Nordhoff et al., 20122013). However, it must be noted that if there are fewer than 0.1 377 
x106 sperm/ml present in the semen sample on freezing, then the success of semen cryopreservation 378 
is likely to be significantly reduced. Most cancer patients have reduced semen parameters at the 379 
time of cryopreservation that will cause a decline in sperm quality after thawing. Never-the-less 380 
successful inseminations with samples stored for cancer patients have been documented and range 381 
from 5 to 16% of patients (van Casteren et al., 2008b) provided that semen quality is high post-382 
thaw. When IVF or ICSI are applicable using cryopreserved spermatozoa success rates are 383 
comparable to standard IVF and ICSI procedures in infertile couples. Indeed, depending on the 384 
Centre, pregnancy rates of 23-57% have been recorded for fertility preservation patients, (Agarwal 385 
et al., 2004; Freour et al., 2012; Hourwitz et al., 2008; Schmidt et al., 2004; van Casteren et al., 386 
2008b). To date no adverse effect of the combination of cryopreservation of semen and subsequent 387 
ART has been reported concerning the health of the offspring.  388 
 389 
For patients with non-obstructive azoospermia, severe oligozoospermia, necrozoospermia or 390 
ejaculation disorders, testicular sperm extraction (TESE) and storage are often the only acceptable 391 
means of tissue retrieval for fertility preservation. The same techniques can be applied in 392 
oncological (adolescent or adult) patients with azoospermia with good results prior to cancer 393 
treatment. Post-therapeutically, TESE has also been used successfully to obtain sperm in up to 50% 394 
  
18 
of cases of persistent azoospermia with previous failure of cryopreservation or when 395 
cryopreservation had not been considered (Hsiao et al., 2011) (Table 2). The TESE procedure 396 
requires surgical intervention, either with local or general anaesthesia with higher recovery rates 397 
obtained following microsurgical techniques (Donoso et al., 2007; Ramasamy et al., 2009; Colpi et 398 
al., 2009). If microsurgery is not available, multifocal testicular biopsies from different sites of the 399 
testis can be used to increase the chance to detect focal spermatogenesis (Tournaye et al., 2006; 400 
Dieckmann et al., 2007). However, this procedure may have a negative impact on the 401 
vascularisation of the testis following the surgery. In patients with ejaculation disorders either 402 
medical or interventional treatments have been described (Sonksen and Ohl, 2002) but how widely 403 
they are used is unclear.  404 
 405 
Testicular tissue preservation for young patients  406 
There is increasing evidence of the use of testicular tissue cryopreservation as a means to preserve 407 
the fertility of prepubertal and peripubertal boys of up to 16 year-old (Wyns et al., 2011). This 408 
statement is supported by the findings of a recent questionnaire from the ESHRE Task Force on 409 
Fertility Preservation that was distributed to 24 European and Israeli University hospitals prior to 410 
December 2012. Of the 14 respondents, half (n=7) were actively offering testis tissue cryobanking 411 
for fertility preservation in boys and adolescents, the remainder were considering the 412 
implementation of a tissue-based fertility preservation program for boys undergoing oncological 413 
treatments (Table 3). At the time of the survey, more than 260 young patients had already 414 
undergone testicular tissue retrieval for fertility preservation although the number of cases reported 415 
between Centres was highly variable (range 8-98) (Table 3). The age range of patients who had 416 
banked tissue was comparable between Centres and ranged from less than 1 year to 16 years of age. 417 
With very few exceptions, the greater majority of preserved tissue samples were still in cryostorage 418 
at the time of survey. While the majority (n=6) of Centres had cryobanked testicular tissue from 419 
boys prior to oncological treatments for the indications detailed in Table 4, the remaining 4 Centres 420 
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had also preserved testicular tissue from patients with non-malignant indications that carried a high 421 
risk for fertility loss. One Centre had exclusively collected testicular tissue from Klinefelter 422 
patients. All Centres preserving testicular tissue in this survey had used slow (equilibrium) freezing 423 
protocols to preserve tissue integrity during long-term storage at liquid nitrogen temperatures. The 424 
majority of Centres preserving tissue used Dimelthyl Sulphoxide (DMSO) combined with sucrose 425 
as the preferred cryoprotective agents. Only 1 Centre had used an ethylene glycol-based protocol.  426 
 427 
 428 
5. Management Of Fertility Preservation In Prepubertal Boys And Adolescents 429 
Fertility preservation management is a multidisciplinary task employingrequires a specialist team of 430 
highly trained physicians and nurses involved in both oncology and reproductive medicine. Indeed, 431 
identifying and educating key staff capable of initiating discussions on fertility preservation is vital 432 
to the success of fertility preservation strategies (Nagel and Neal, 2008). . Information flow must be 433 
accurate and timely and is vital to the uptake of fertility preservation services by young patients and 434 
their parents. Pediatric oncologists, together with oncology nurses and reproductive medicine 435 
specialists will have multiple interactions with patients and parents prior to the initiation of 436 
treatment and are therefore in an ideal position to discuss the late effects of gonadotoxic treatment, 437 
quality of life and survivor issues with patients and their families (Vadaparampil et al., 2007). Close 438 
collaboration between pediatric, oncologic and fertility specialists (gynecologists, andrologists and 439 
reproductive biologists) is essential for the preparation of sperm or testicular tissue for 440 
cryopreservation. Informative letters and/or presentations during medical meetings allow 441 
oncologists to be aware of spermatogenesis physiology, onset of spermarche and potential fertility 442 
preservation approaches related to age and pubertal status. Clear instructions on who to contact in 443 
the infertility department to discuss the matter on an individual patient basis, unrestricted access to 444 
educational patient information and rapid and flexible access to medical consultation and surgical 445 
biopsy for tissue recovery and storage should be provided to accommodate the short time-scales 446 
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infertility specialist by pediatric hematologists and oncologists before gonadotoxic treatment is 447 
initiated (Redig et al., 2011). Therefore, oncologists face a challenging decision-making process 448 
that must take into account the possibility of delaying therapy and achieving optimal curative 449 
success rates. Delaying therapy by a few days is only appropriate when there is a good prognosis, 450 
combined with a high risk of permanent infertility and no evidence of decreased success rate of 451 
treatment. Such decisions should be guided by an institutional policy and shaped by physicians, 452 
mental health professionals and an ethical board. During this emergency consultation with a fertility 453 
specialist, children (when applicable, usually from the age of 5 with adapted words) and adolescents 454 
should receive adapted counseling and appropriate information on sexual maturation, including 455 
pubertal events and testicular maturation and reproduction (with content linked to age, physical 456 
examination and previous history). It is essential that the clinical team has a detailed knowledge of 457 
the hormonal events and testicular physiology around puberty in order to provide patients /parents 458 
with accurate information. Parents need to be made aware of- and be receptive to- fertility 459 
preservation options while young patients must also be receptive to discussions about fertility 460 
preservation, suitable to their age, and be made aware of their health status, as appropriate. Access 461 
to institution guidelines, human resources and appropriate educational materials are also vital 462 
(Vadaparampil et al., 2008). There is currently some debate as to whether testicular tissue should be 463 
frozen in conjunction with sperm freezing as discrepancies may also be found in the 464 
presence/absence of spermatozoa between intraoperative analyses and definitive 465 
anatomopathological observations (Wyns et al., 2011). Furthermore, the protocols used to preserve 466 
mature germ cells differ from those used to preserve spermatogonia. This raises the question of 467 
whether testicular tissue should be cryopreserved using both protocols during peri-pubertal life 468 
from the age of 12. Such a recommendation is based on concerns about the reproductive potential of 469 
immature, haploid germ cells retrieved at early pubertal stages. Indeed, although in vitro maturation 470 
of round spermatids from adult testicular tissue has already led to the birth of healthy offspring 471 
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(Tesarik et al, 1999), the fertilization competence of immature haploid cells retrieved from peri-472 
pubertal tissue still remains to be proven.  473 
 474 
Where there is a risk of gonadal damage and fertility loss, patients should be referred to the 475 
infertility specialist by pediatric hematologists and oncologists before gonadotoxic treatment is 476 
initiated (Redig et al., 2011). Therefore, oncologists face a challenging decision-making process 477 
that must take into account the possibility of delaying therapy and achieving optimal curative 478 
success rates. Delaying therapy by a few days is only appropriate when there is a good prognosis, 479 
combined with a high risk of permanent infertility and no evidence of decreased success rate of 480 
treatment. Such decisions should be guided by an institutional policy and shaped by physicians, 481 
mental health professionals and an ethical board. During this emergency consultation with a fertility 482 
specialist, children (when applicable, usually from the age of 5 with adapted words) and adolescents 483 
should receive adapted counseling and appropriate information on sexual maturation, including 484 
pubertal events and testicular maturation and reproduction (with content linked to age, physical 485 
examination and previous history). It is essential that the clinical team has a detailed knowledge of 486 
the hormonal events and testicular physiology around puberty in order to provide patients /parents 487 
with accurate information. Parents need to be made aware of- and be receptive to- fertility 488 
preservation options while young patients must also be receptive to discussions about fertility 489 
preservation, suitable to their age, and be made aware of their health status, as appropriate. Access 490 
to institution guidelines, human resources and appropriate educational materials are also vital 491 
(Vadaparampil et al., 2008). There is currently some debate as to whether testicular tissue should be 492 
frozen in conjunction with sperm freezing as discrepancies may also be found in the 493 
presence/absence of spermatozoa between intraoperative analyses and definitive 494 
anatomopathological observations (Wyns et al., 2011). Furthermore, the protocols used to preserve 495 
mature germ cells differ from those used to preserve spermatogonia. This raises the question of 496 
whether testicular tissue should be cryopreserved using both protocols during peri-pubertal life 497 
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from the age of 12. Such a recommendation is based on concerns about the reproductive potential of 498 
immature, haploid germ cells retrieved at early pubertal stages. Indeed, although in vitro maturation 499 
of round spermatids from adult testicular tissue has already led to the birth of healthy offspring 500 
(Tesarik et al, 1999), the fertilization competence of immature haploid cells retrieved from peri-501 
pubertal tissue still remains to be proven.  502 
 503 
 504 
Cryopreservation of spermatozoa for boys and adolescents  505 
The collection and cryopreservation of spermatozoa is the only validated,  clinical technique 506 
available currently to safeguard the future fertility of peripubertal boys and adolescents (Figure 2). 507 
Therefore, sperm Sperm banking should always be used offered as the first line treatment in those 508 
young patients who can produce a semen sample since live births can be obtained after ICSI even 509 
when only a few spermatozoa are available (Palermo et al., 1992). Although semen samples can be 510 
obtained from boys from the age of 12 onwards (Bahadur et al., 2006) the onset of sperm 511 
production (spermarche) in boys can be very difficult to predict. Spermatogenesis is known to start 512 
at very early stages of pubertal development (Muller and Skakkebaeck, 1983; Hovatta, 2001) and 513 
may occur before the ability to produce an ejaculate (Nielsen et al., 1986). Moreover, gonadal 514 
maturation in boys is not characterized by critical visible events as is the case in girls, and defining 515 
the age below which the experimental immature testicular tissue cryopreservation would be the best 516 
choice for fertility preservation is not easy because of the great variability in age at spermarche (Ji 517 
and Oshawa, 2000). At the onset of spermarche there also appears to be a wide variation in both 518 
testicular size and secondary sex characteristics (Nielsen et al., 1986). Spermarche may occur when 519 
little or no pubic hair has developed and when the testicular volume has increased only slightly. 520 
Indeed, the presence of spermatozoa (based on spermaturia, as a marker for spermarche) was found 521 
in 5% of clinically prepubertal boys and in 50% of boys between Tanner stage II and III for pubic 522 
hair pattern. Serum hormone levels are not useful to predict sperm production since at the onset of 523 
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spermaturia, gonadotrophin and testosterone concentrations are low and only start to increase after 524 
Tanner stage II (Radicioni et al., 2005; van Casteren et al., 2008a). Correlations between 525 
spermaturia and clinical parameters have been established (Schaefer et al., 1990), but do not allow 526 
clear cut-offs for allocating a boy to either sperm banking or spermatogonial preservation. The 527 
detection and preservation of sperm extracted from morning urine is not considered an appropriate 528 
therapy because of its time-consuming nature. In cases of failure to produce a semen sample by 529 
masturbation, assisted ejaculation techniques such as penile vibratory stimulation or electro-530 
ejaculation under general anesthesia should be considered as a second-line treatment option. These 531 
methods may have advantages over experimental techniques such as immature testicular tissue 532 
sampling as the former will facilitate collection and storage of mature sperm. Since there is no 533 
reliable sensitive estimate for the presence of spermatozoa in the testes, intra-operative examination 534 
of testicular tissue (Wyns et al., 2011) should be carried out to determine the presence of either 535 
spermatozoa or late spermatids in order to choose an appropriate freezing protocol.  536 
   537 
 Once collected, liquefied ejaculates should be analysed according to the guidelines of the 538 
World Health Organization (WHO, 2010) and standard parameters of sperm concentration total 539 
number of spermatozoa, morphology and motility determined prior to cryopreservation. According 540 
to WHO recommendations, if possible sufficient specimens should be stored to provide 10 or more 541 
inseminations, in order to ensure a good chance of pregnancy. However, when sperm preservation 542 
is conducted in an emergency situation in response to a young patient’s disease it is not always 543 
possible to adhere to WHO recommendations. For samples with severely reduced semen quality 544 
and/or only a few motile spermatozoa and sperm suspensions from surgically retrieved 545 
spermatozoa, it may be necessary to concentrate the sperm into a minimum volume by 546 
centrifugation before the addition of cryoprotective agents and sample preservation according to 547 
local practises. At the time of writing, the evidence base for vitrification of spermatozoa or 548 
testicular tissue using specialist vitrification devices is limited but this approach may prove useful 549 
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in the future (Isachenko et al., 2004; 2005; Poels et al., 2013). The storage of individual sperm in 550 
empty zona pellucida may be advocated in some situations (Cohen et al., 1997).  In all cases, the 551 
best cryobiology practises used for the preservation and long-term storage of samples are advocated 552 
but the procedures used will be informed by the physical principles and the specific properties and 553 
nature of the cells/tissues to be stored (Benson et al., 2012).  554 
 555 
 556 
Cryopreservation of testicular tissue in prepubertal boys and adolescents  557 
In cases where no semen can be collected, the experimental techniques of cryopreservation of 558 
testicular tissue or suspensions of immature testicular cells including SSCs should be considered 559 
(Figure 2). To minimise trauma to the patient, the surgical recovery of testicular tissue should be 560 
combined with other interventions requiring anaesthesia, such as bone marrow sampling or 561 
implantation of venous ports. Close interdisciplinary cooperation between paediatric oncologist and 562 
urologists or paediatric surgeons is therefore required. To date 4 freezing protocols for human 563 
immature testicular tissue have been described using cryoprotective agents that that range from 564 
1.5M ethylene glycol and sucrose (Kvist et al., 2006), 0.7M DMSO (Keros et al., 2005; 2007) or 565 
0.7M DMSO and sucrose (Wyns et al., 2007; 2008; Poels et al., 2014). Expensive bio-freezers may 566 
not be essential for the cryopreservation of human testicular tissue (Baert et al., 2013). Indeed, 567 
evaluation of human immature testicular tissue following xenotransplantation into nude mice 568 
suggests that vitrification may be as effective for tissue preservation as slow freezing methods 569 
(Curaba et al., 2011; Poels et al., 2013). To maximise the quality and viability of human testicular 570 
tissue post thaw all aspects of the tissue collection and processing, the type and concentration of 571 
cryoprotectants used as well as the cooling and warming protocols must be fully optimised. Since 572 
the reproductive potential of cryopreserved immature testicular tissue has still to be proven in 573 
humans, the technique remains experimental and no one preservation protocol has been shown to be 574 
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superior over any other published method (Kvist et al., 2006; Keros et al., 2007; Wyns et al., 2008; 575 
Baert et al., 2013; Goossens et al., 2013; Poels et al., 2013).  576 
 577 
Biosecurity and long-term storage of tissues for fertility preservation  578 
The long-term storage of fertility preservation samples, whether in the form of semen sperm, 579 
epididymal sperm or testicular tissue samples, requires that the patient and/or his parents maintain a 580 
contract with the host institution to guarantee the continued storage of tissue and that the storage 581 
facility adheres to national guidelines and international recommendations for good tissue banking 582 
practices. Annual tissue banking charges may apply according to local practices. The associated 583 
costs may be covered by the patient or their family, or be borne by health insurance or the hospital 584 
or an institutional grant (Table 3). Provided optimal low temperatures are maintained throughout 585 
long-term freeze-banking there is no obvious deterioration of sperm quality with time. Indeed, 586 
children have been born from semen stored for over 28 years (Feldschuh et al., 2005). However, 587 
maintenance of the physical- and bio- security of fertility preservation samples is key if samples are 588 
to be stored for many decades.  Adherence to national guidelines and international 589 
recommendations for good tissue banking practices is essential from the outset in terms of 590 
witnessing, sample processing and labelling, infection screening , and the need for regular cryobank 591 
audit and patient follow-up. There is also a significant chance that fertility preservation samples will 592 
need to be transported at some point in their history either for continuation of storage if patients 593 
move or prior to their use for fertility restoration in later life.  594 
 595 
 596 
6. Fertility Restoration Using Cryopreserved Testicular Tissues And Stem Cells  597 
Development of the procedures used for the preservation of SSCs and testicular tissues from boys 598 
and adolescents is far more advanced than research into the methods needed to realise the fertile 599 
potential of these cells and these techniques have yet to be proven to be safe for clinical use. In 600 
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summary, fertility restoration strategies include the auto-transplantation of a suspension of SSCs by 601 
injection into the testis to restore spermatogenesis or auto-transplantation of frozen-thawed 602 
testicular grafts back into the testis or an ectopic site. Where there is any risk of reintroduction of 603 
malignant cells via the transplant then the only option is to  and the growth and maturation ofe the 604 
SSCs in vitro. These issues are discussed in full below. 605 
 606 
Propagation and autotransplantation of spermatogonial stem cells  607 
Currently, SSC injection is considered the most promising tool for fertility restoration in pre-608 
pubertal cancer patients. The technique was originally described in the mouse (Brinster and 609 
Zimmerman, 1994) and it has been successfully used to infuse SSC through the efferent duct into 610 
the rete testis of sterile recipients with the resultant reinstatement of spermatogenesis and the 611 
restoration of fertility (Brinster and Averbock 1994). However, because of differences in anatomy 612 
and consistency and the larger testis size, injection of SSC via the rete testis, has proved to be a 613 
better treatment site for species such as the bovine, primate, and human (Schlatt et al., 1999; Ning 614 
et al., 2012).  615 
 616 
If SSCs are to be used to restore male fertility, then they first need to be isolated and propagated in 617 
vitro before they can be autotransplanted in the numbers required to efficiently recolonize the testis 618 
and reinstate spermatogenesis. For example, it has been demonstrated that only 5-10% of 619 
transplanted SSCs result in colony formation in the recipient testis and the extent of donor-derived 620 
spermatogenesis is directly related to the number of transplanted cells (Dobrinski et al., 1999). 621 
Furthermore, murine studies have indicated that factors such as glial cell line derived neurotrophic 622 
factor (GDNF)–which facilitates self-renewal of the SSCs and supports SSC replication in vitro 623 
(Kanatsu-Shinohara et al., 2003) are essential for SSC propagation. This evidence has been 624 
replicated in several species (Honaramooz et al., 2002, Izadyar  et al., 2003, Schlatt et al., 1999, 625 
Nobrega et al., 2010, Aponte et al., 2008). Importantly, in the context of human fertility restoration 626 
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adult and prepubertal human SSCs have been successfully grown in vitro, without losing their stem 627 
cell capacity or ability to colonize the seminiferous tubules upon xenotransplantation (Sadri-628 
Ardekani et al., 2009, Sadri-Ardekani et al., 2011). A number of other studies, mostly in mice, have 629 
evaluated the recovery of fertility after non-cultured SSC injection. Transplanted mice were able to 630 
produce live born offspring with normal birth weights, growth rates and fertility (Goossens et al., 631 
2009). No numerical chromosomal aberrations were detected in spermatozoa from transplanted 632 
males, or in their offspring (Goossens et al., 2010). Importantly, studies of methylation patterns and 633 
histone modifications in post-transplantation germ cells revealed that apart from two minor 634 
alterations, epigenetic marks following uncultured mouse SSC injection were not different 635 
compared to control spermatogenesis (Goossens et al., 2009; Goossens et al., 2011). Most recently 636 
Rhesus monkey SSCs have been injected under slow constant pressure into the rete testis under 637 
ultrasound-guidance, both autologously and allogeneically and into both adult and prepubertal 638 
rhesus monkeys sterilised by alkylating chemotherapy. Following the completion of 639 
spermatogenesis in vivo, sperm cells that were able to fertilize oocytes by ICSI were found in the 640 
ejaculate of recipients (Hermann et al., 2012). While the demonstration of functional donor 641 
spermatogenesis following SSC transplantation in primates is an important milestone towards using 642 
SSC to restore human fertility it remains vitally important to prove that the epigenetic programming 643 
and stability of SSC are not compromised following cryopreservation, culture and transplantation in 644 
humans (Struijk et al., 2013). 645 
 646 
Restoration of fertility by autotransplantation of testicular tissue   647 
Transplantation of fragments of testicular tissue provides an alternative strategy to the use of SSC 648 
suspensions. This approach maintains the SSCs within their non-exposed natural niche, thus 649 
preserving the interactions between the germ cells and their supporting somatic cells. Nutrients and 650 
hormones from the body will reach the graft and induce spermatogenesis and the resultant sperm 651 
can be extracted and used in ICSI procedures. Autologous transplantation of the testicular biopsy 652 
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back into the testis (Van Saen et al., 2009), scrotum (Wyns et al., 2007) or ectopically under the 653 
skin (Jahnukainen et al., 2007) can however only be used to restore spermatogenesis if the presence 654 
of malignant cells can be excluded. In initial research using mouse models, testis grafts were placed 655 
at ectopic sites such as in the peritoneal space, on the ear or under the back skin (Boyle et al., 1975; 656 
Schlatt et al., 2002). However, these grafts become sclerotic or showed meiotic arrest. Autologous 657 
grafting to several locations in the irradiated primate body also showed that spermatogenesis could 658 
only be re-established when the graft was placed in the scrotum but the efficiency of fertility 659 
restoration remained poor (Jahnukainen et al., 2012). Transplantation of the tissue under the tunica 660 
albuginea of the testis (intra-testicular grafting) might improve results as, in mice, this technique 661 
has proved to be highly efficient with the re-establishment of full spermatogenesis in all of the 662 
grafts (Van Saen et al., 20082009). At the time of writing, little is known about the functionality of 663 
the sperm generated in such grafts as only a few groups have addressed this important question 664 
using mouse and rabbit donor tissue. However, with sperm retrieved from ectopic and intra-665 
testicular mouse allografts, insemination studies using ICSI have demonstrated that the spermatozoa 666 
so derived were able to support full-term development of the progeny (Schlatt et al., 2003; Ohta and 667 
Wakayama, 2005). It was also possible to obtain offspring using rabbit sperm that had developed in 668 
intra-testicular transplanted xenografts (Shinohara et al., 2002). Normal blastocyst development has 669 
been achieved in vitro following ICSI with sperm from ectopic porcine and monkey xenografts 670 
(Honaramooz et al., 2004; 2008; Nakai et al., 2010).  671 
 672 
In vitro spermatogenesis  673 
The major hurdle which must be overcome in patients with a prior haematological malignancy 674 
when restoring fertility by autotransplantation of propagated SSCs or testicular tissue is the risk of 675 
reintroducing residual malignant cells via the transplanted tissue. While it is possible to avoid the 676 
transfer of malignant cells by using testicular xenografts, the risk of zoönosis means that 677 
xenografting of human testicular tissue is unlikely to provide an acceptable clinical solution for 678 
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fertility restoration. Although, positive and negative cell sorting strategies have the potential to 679 
target and remove cells from cultured mouse SSC populations and after xenografting (Dovey et al., 680 
2013; Hermann et al., 2011). Sorting protocols using magnetic activated cell sorting (MACS), 681 
FACS or differential plating have been found to have variable efficiency when used to enrich  682 
human SSCs (Geens et al., 2006; Geens et al., 2011; Nickkholgh et al., 2014a). Thus, at the time of 683 
writing autotransplantation of cell suspensions or tissues still runs the risk of reintroducing cancer 684 
via the graft.  685 
 686 
The risk of reintroduction of malignant cells via the autograft may be circumvented by in vitro 687 
spermatogenesis. In vitro-derived spermatozoa that are free from residual disease can then be used 688 
to inseminate oocytes using ICSI. Strategies which support the in vitro growth and differentiation of 689 
germ cells include the 3 dimensional (3D) culture of testicular cells (Stukenborg et al., 2008) or 690 
organ culture (Sato et al., 2011). The main difference between the two approaches lies in the fact 691 
that in organ culture the testicular biopsy remains intact and is layered upon an island of agar that is 692 
maintained in a liquid medium. In 3D culture, the germ cells are dissociated from their somatic cells 693 
prior to culture and they are then suspended in medium containing 35 and 50% agar, the so-called 694 
Soft-Agar-Culture-System. In both systems SSCs are co-cultured with somatic cells from the same 695 
biopsy so resembling the in vivo situation and supporting two-way communication between the 696 
different cellular compartments. In the mouse model, in vitro spermatogenesis has been successful 697 
up to the elongated spermatid stage of spermatogenesis but so far offspring have only been 698 
generated with sperm derived following organ culture (Sato et al., 2011). Although encouraging 699 
results have recently been obtained regarding the genetic and epigenetic stability of human SSCs 700 
during long-term culture (Nickkholgh et al., 2014b), the fertility of in vitro derived sperm have still 701 
to be established before the clinical value of this type of experimental approach can be fully 702 
assessed. When no germ cells are available in the initial testis biopsy, an alternative option may be 703 
the in vitro derivation of sperm cells from the patient’s somatic cells, such as skin fibroblasts, by 704 
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induced pluripotency or transdifferentiation of these cells (Yang et al., 2012). This approach is 705 
however still in its infancy. 706 
 707 
 708 
7. Follow-Up Of Patients At Risk Of Gonadal Dysfunction Following Treatment For 709 
Childhood Cancer  710 
Predicting the likelihood of gonadal dysfunction in individual patients who are survivors of 711 
childhood disease may be difficult. Guidance on this topic has recently been published (Wallace et 712 
al., 2013). Measurements of gonadotrophins and testosterone in pre-pubertal patients are unlikely to 713 
be helpful as the hypothalamo-pituitary-gonadal axis is not active priori to puberty (Mann and 714 
Fraser 1996). Therefore, the accurate clinical assessment of growth during childhood using 715 
appropriate growth charts is very important, particularly in the context of pubertal staging as 716 
puberty may be delayed (or occasionally advanced) following cancer treatment. Treatment for 717 
childhood cancer may result in central effects on the hypothalamus and/or pituitary that will affect 718 
gonadotrophin production, or primary testicular failure may result from direct damage to the testis 719 
(Mitchell et al., 2009). Leydig cell damage may reduce testosterone production and hence delay or 720 
arrest puberty (>14y), whilst effects on Sertoli cells and germ cells of the seminiferous epithelium 721 
may impair spermatogenesis and decreased adult testicular size. Normal pubertal development with 722 
full hair- and penis- growth indicates normal Leydig cell function, irrespective of testicle size. TAs 723 
described earlier, the seminiferous epithelium is more sensitive to the effects of cancer treatment 724 
than the Leydig cells and patients may still have small adult testis size and impaired fertility despite 725 
having undergone a normal puberty with sufficient testosterone production (Jahnukainen et al., 726 
2011a). 727 
 728 
Assessment of male pubertal development should include: (i) measurement of testicular volume; (ii) 729 
Tanner staging of secondary sexual development; (iii) measurement of serum FSH, LH, 730 
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testosterone and inhibin B (if available); (iv) yearly bone age x-ray from any signs of initiation until 731 
completion of puberty. For patients with delayed or arrested puberty (>14y), treatment with 732 
increasing doses of testosterone should be considered (Kenney et al., 2012). Once puberty has been 733 
established, measurement of testicular volumes, and FSH and inhibin B levels may also indicate 734 
effects on the seminiferous epithelium and hence spermatogenesis (Lahteenmaki et al., 2008). 735 
Azoospermia is likely if the testicular volumes are <10ml and the FSH is >10 IU/L (Muller et al., 736 
1996; Siimes et al., 1995). Where possible and, as requested by the patient himself, semen analysis 737 
can be performed and the patients referred for ART, as appropriate. Should semen analysis reveal 738 
azoospermia, it is worth repeating the test annually, as the recovery of surviving stem cells 739 
(spermatogonia) may take several years.  740 
 741 
Post-surgical complications 742 
While the collection and storage of testicular tissue can be proposed as a means of fertility 743 
preservation in young patients who are unable to produce a semen sample, the procedure is 744 
experimental and invasive and The evidence from testicular biopsy in adults (Schlegel and Su 1997; 745 
Manning et al., 1998) suggest that the risk of the biopsy procedure itself should not be overlooked 746 
in younger patients (Mitchell et al., 2009). Immediate surgical complications include bleeding and 747 
infection where as later complications may be indicative of damage to the remaining testis. In a 748 
study of 64 men with non-obstructive azoospermia undergoing biopsy for sperm extraction, 82% 749 
had hypoechoic lesions indicative of haematoma 3 months after biopsy, which had resolved by 6 750 
months leaving linear scars (Schlegel and Su 1997). Another study in adults with obstructive 751 
azoospermia who underwent a large-bore needle, testicular biopsy demonstrated no difference in 752 
LH, FSH or testosterone levels at 4 weeks of follow-up compared to the pre-biopsy levels (Steel et 753 
al., 2001). In contrast, a large open testicular biopsy has been associated with a significant reduction 754 
in testosterone at 6 months post biopsy; although testosterone concentrations increased by 12 755 
months but did not not revert to original levels (Manning et al., 1998).  756 
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 757 
The evidence base concerning the effects of testicular biopsy in prepubertal patients is limited. In a 758 
US study of 24 boys, 14 underwent testis tissue biopsy without any short term complications and no 759 
post-operative orchitis or reports of excessive pain (Ginsberg et al., 2010). In a series of 62 760 
prepubertal and peripubertal patients under 16 years-old, who underwent unilateral testicular biopsy 761 
for fertility preservation, no short-term post-surgical complications were observed (Wyns et al., 762 
2011). Longer-term follow up of patients undergoing testicular biopsy has been reported in 763 
cryptorchid boys undergoing orchidopexy (Patel et al., 2005). In this study 112 boys were followed 764 
up for a mean of 11 years post-surgery (age range 18-29). None of the patients required re-operation 765 
for bleeding, received treatment for post-operative orchitis or sustained loss of a testis. An 766 
ultrasound scan at follow-up revealed no cases of testicular atrophy or biopsy related damage to the 767 
testis, or development of anti-sperm antibodies (Patel et al., 2005). In a study of 23 patients who 768 
underwent an open wedge testis biopsy during treatment or on cessation of treatment in childhood 769 
for acute lymphoblastic leukaemia, 8 patients receiving standard risk therapy had FSH, inhibin B 770 
and testosterone levels comparable to the general population (Nurmio et al., 2009).  771 
 772 
 773 
Future fertility 774 
Determining Tthe effects impact of prepubertal testicular biopsy on on future fertility is difficult to 775 
predict. for prepubertal patients, given the limited amount of tissue taken and the favourable results 776 
regarding post-operative complications. To date the evidence base suggests that the procedure itself 777 
is unlikely to result in a significant impairment of fertility. Nevertheless, Meticulous record keeping 778 
and monitoring of young patients who have undergone a biopsy is vital to ensure that there are no 779 
complications related to the procedure including any damage to the remaining testis tissue. In 780 
addition, meticulous records must be kept by institutions undertaking these procedures and the 781 
outcomes reported in the literature. Multi-centre studies to facilitate data collection fromon these 782 
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relatively rare patients will are needed to provide clearer insights into the requirements for long-783 
term follow-up needed.  784 
 785 
 786 
8. The Ethical and Legal Frameworks For Fertility Preservation In Prepubertal Boys And 787 
Adolescents  788 
The setting for making decisions and developing and implementing fertility preservation strategies 789 
in young boys and adolescents are heavily influenced by life-changing and life-threatening 790 
diagnoses and treatment options that not only distress patients, parents and physicians but also raise 791 
a raft of complex ethical and legal issues. The main ethical justification for interventions associated 792 
with fertility preservation is the need to safeguard the best interests of the child.  This is generally 793 
expressed in a favorable risk-benefit ratio. This balancing is highly complex due to a number of 794 
factors such as: the intervention is performed on incompetent minors; there is a lack of scientific 795 
and clinical evidence of the efficiency and safety of fertility preservation technologies such as testis 796 
and SSC cryopreservation and no proof of principle about their feasibility in humans; and the need 797 
for tissue recovery from young patients generates a highly emotional and stressful situation for both 798 
patients and parents. In the absence of evidence regarding future success, utilization rate, 799 
psychological consequences etc., the current position seems to be largely determined by 2 elements: 800 
(i) the importance attributed to the wish to have genetically related children (patient autonomy), and 801 
(ii) the optimism regarding the development of medical technology in the future (Murphy, 2010). 802 
 803 
A key The first question that must be addressed in consideration of fertility preservation strategies 804 
is to whom storage of sperm and/or testicular tissue should be offered (Murphy 2010). Indeed, 805 
recent surveys suggests that the issue of sterility is hardly discussed with parents of boys 806 
undergoing chemotherapy (Lee et al., 2006; Anderson et al., (2008). There are 2 schools of thought. 807 
It can be argued that as paediatric oncology teams treat a patient with the intent to cure, then 808 
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fertility preservation strategies should be discussed with all young patients and their families. The 809 
alternative view, however, is that young patients and/or their parents should only be approached to 810 
discuss fertility preservation options if there is both not only a good prognosis and but also a high 811 
risk of permanent infertility (Wallace et al., 2005).  812 
 813 
The diagnosis of genetic disease or cancer in a child inevitably creates a highly distressing and 814 
stressful situation that may seriously hamper rational decision-making. For many, cancer treatment 815 
will have to start as soon as possible, resulting in considerable time pressure. Moreover, other 816 
intervening psychological forces such as feelings of guilt and panic and mechanisms such as 817 
anticipated decision regret should be taken into account (Van Den Broecke et al., 2001). Still, 818 
careful counseling can lead to a well-considered informed consent from either the patient or the 819 
parents (Ginsberg et al., 2010). In all cases iInformed consent from parents or legal guardians 820 
should be taken before tissue is harvested. Even when minors are legally incompetent, an effort 821 
should be made to inform them about the implications of the procedure (at a level appropriate for 822 
their age and maturity) and to obtain assent (Bahadur et al., 2001). The consent form must include 823 
sections on safety (mentioning the possibility of both expected and unexpected adverse events) and 824 
on the experimental nature of testis freezing and SSC preservation and that the research methods for 825 
fertility restoration in animals have not yet been successfully translated to humans.   826 
 827 
The risks of fertility loss must be balanced against the potential for fertility restoration from stored 828 
samples and explained to each individual child and his parents to make sure that they understand 829 
that there is no guarantee of success. In this context it is useful to consider the procedure as a two-830 
step process. Phase 1 involves the collection and storage of semen as the priority or the recovery of 831 
testicular tissue if semen collection is impossible. Phase 2 incorporates the replacement and/or 832 
subsequent use of the material for fertility restoration. The risks associated with these two phases 833 
differ. While tThe collection and cryopreservation of semen for fertility preservation is an 834 
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established, non-invasive, technology for adolescents with cancer (Daudin et al., 2015). In marked 835 
contrast, ), the recovery of a testicular biopsy from boys in whom sperm is not yet produced must 836 
be regarded as an experimental procedure as key issues such as how much tissue to collect, which 837 
preservation and fertility restoration techniques to use, and the potential risk of reintroduction of 838 
malignant cells during fertility restoration etc. all remain to be resolved. The direct costs of phase 1 839 
(general anesthesia, pain etc.) are relatively small, especially when they can be combined with 840 
necessary cancer-related interventions. Nevertheless, attention should be paid to unknown risk 841 
factors such as complications after testis biopsy in prepubertal boys and the possibility of 842 
reintroduction of cancer in the patient or defects in the offspring. Both the beneficence and the non-843 
maleficence principle imply that the cost-benefit balance should be maximized. This means that the 844 
least harmful and the most beneficial intervention(s) should be chosen, taking into account the other 845 
aspects of the intervention. It should be made clear to the patient and his parents that storage does 846 
not guarantee that he has a right to have the material replaced in the future. 847 
 848 
When calculating the benefits for the patient, one should not only look at the possibility to have 849 
one’s own genetic children in the future but also at the psychological benefits that having testicular 850 
tissue in storage may have on the patient both now and in the future. Stored material may put 851 
patients at ease, give them hope, promote recovery and create less stress (Crawshaw and Sloper, 852 
2010). However, emphasis should be put on the experimental nature of the intervention to avoid 853 
therapeutic misconception (the failure to distinguish between research and treatment) and 854 
unrealistic expectations. If the cryostored material proves to be useful for reproductive purposes in 855 
the future, it will most likely be with limited success. Clinics offering cryobanking are morally 856 
obliged to participate in data collection and follow-up research in order to improve information 857 
provision and decision-making.  858 
 859 
 860 
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 861 
9. The Legal Context Of Fertility Preservation In Boys and Adolescents 862 
The application development and uptake of fertility preservation strategies in prepubertal boys 863 
assumes that the needs be supported by the creation of suitable legislationory/ and regulatory 864 
frameworksion. Legal rules should cover key points such as: differences associated with the 865 
handling and storage of gametes vs. gonadal tissue; maximal storage period- storage for several 866 
decades may be required; and tissue disposal in the event of death. The possibility of (partial) 867 
reimbursement of treatment and storage costs through some form of insurance and rules about 868 
proxy consent by parents or legal guardians regarding tissue collection and storage may also need to 869 
be considered. Further discussion of the ethical  and legal issues surround fertility preservation in 870 
boys and adolescents is provided in the accompanying long version of this paper. within each 871 
country covers a number of points including: the possibility to store the material (gametes and/or 872 
gonadal tissue) for several decades if necessary; a regulation detailing how to dispose of the 873 
material in the event of death; the possibility of (partial) reimbursement of treatment and storage 874 
costs through some form of insurance; and rules about proxy consent by parents or legal guardians 875 
regarding tissue collection and storage. The results of the current survey of the uptake of testicular 876 
tissue cryopreservation for boys and adolescents indicated that testicular tissue collection and 877 
cryopreservation is already in limited use either with approval of the local ethics committee of the 878 
University or Hospital or according to the current bioethics law as for example in France. In all 879 
cases procedures were considered to be experimental such that no costs were charged to the 880 
patients. The costs for tissue retrieval and cryobanking as well as for analysis of tissue samples 881 
prior to and after cryobanking were covered either by public health insurance or by hospital 882 
research grants or grants from public or private funding agencies. One Centre charged patients a 883 
yearly fee for continued cryostorage of samples. 884 
 885 
The legal rules relevant for fertility preservation vary on 3 points: differences regarding handling 886 
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 889 
10. Future Challenges For Fertility Preservation In Boys and Adolescents 890 
The development of strategies for fertility preservation of fertility in prepubertal boys and 891 
adolescents is still in its early infancy and represents a balance between biological, clinical and 892 
technical knowns, technological unknowns and ethical and legal questions. Progress in this field is 893 
very encouraging and our ability to it has enabled us to design treatment algorithms that have the 894 
potential to safeguard the future fertility of these young patients by the cryopreservation of sperm 895 
when present or the use of new technologies of SSC and/or testicular tissue freezing when sperm 896 
are absent (Figure 2). The algorithm is built on a detailed understanding of human spermatogenesis 897 
combined with significant improvements in cancer treatments and advances in cryobiology and 898 
stem cell technology. However, although the field is advancing there are many important questions 899 
that remain unanswered (Table 5). Experimental techniques such as SSC and testicular tissue 900 
freezing, while promising, require further validation as efficient and safe methods for clinical use 901 
before they can be fully integrated into routine treatment strategies and the decision making process 902 
used to ensure the most effective use of cryopreserved tissues for the future restoration of fertility in 903 
these patients.  904 
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